Moderna has entered into a licensing deal with Generation Bio to develop immune cell and liver treatments. The partnership will expand the applications of both company’s platforms through the finding and development of lipid nanoparticles (LNPs) using Generation’s cell targeted LNP (ctLNP) delivery system. In turn, it aims to develop nucleic acid therapeutics, including ones that are able to reach immune cells and thus advance their non-viral genetic medicines pipeline. “Generation Bio has designed a stealth LNP designed to be…